210 related articles for article (PubMed ID: 36593950)
21. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
22. Targeting mutant p53 stabilization for cancer therapy.
Wang J; Liu W; Zhang L; Zhang J
Front Pharmacol; 2023; 14():1215995. PubMed ID: 37502209
[TBL] [Abstract][Full Text] [Related]
23. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
24. Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast.
Denney AS; Weems AD; McMurray MA
G3 (Bethesda); 2021 Sep; 11(9):. PubMed ID: 34544131
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
[TBL] [Abstract][Full Text] [Related]
26. Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis.
Wang YL; Wu W; Su YN; Ai ZP; Mou HC; Wan LS; Luo Y; Qiu MH; Zhang JH
Phytomedicine; 2020 Mar; 68():153187. PubMed ID: 32097779
[TBL] [Abstract][Full Text] [Related]
27. BCAS3 exhibits oncogenic properties by promoting CRL4A-mediated ubiquitination of p53 in breast cancer.
Zhou Z; Qiu R; Liu W; Yang T; Li G; Huang W; Teng X; Yang Y; Yu H; Yang Y; Wang Y
Cell Prolif; 2021 Aug; 54(8):e13088. PubMed ID: 34240781
[TBL] [Abstract][Full Text] [Related]
28. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
29. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
30. Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells.
Grosset AA; Labrie M; Gagné D; Vladoiu MC; Gaboury L; Doucet N; St-Pierre Y
BMC Cancer; 2014 Nov; 14():801. PubMed ID: 25367122
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
Zhang Y; Xu L; Chang Y; Li Y; Butler W; Jin E; Wang A; Tao Y; Chen X; Liang C; Huang J
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):160-171. PubMed ID: 31471556
[TBL] [Abstract][Full Text] [Related]
32. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Buckley NE; D'Costa Z; Kaminska M; Mullan PB
Cell Death Dis; 2014 Feb; 5(2):e1070. PubMed ID: 24556685
[TBL] [Abstract][Full Text] [Related]
33. BAG2 Overexpression Correlates with Growth and Poor Prognosis of Esophageal Squamous Cell Carcinoma.
Hong YC; Wang Z; Peng B; Xia LG; Lin LW; Xu ZL
Open Life Sci; 2018 Jan; 13():582-588. PubMed ID: 33817129
[TBL] [Abstract][Full Text] [Related]
34. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
35. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
36. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
37. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
38. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
39. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma.
Babu D; Chintal R; Panigrahi M; Phanithi PB
Cell Oncol (Dordr); 2022 Dec; 45(6):1451-1465. PubMed ID: 36284039
[TBL] [Abstract][Full Text] [Related]
40. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
